- Zacks•2 days ago
Novartis (NVS) announced positive top-line data from the phase III ASCEND-4 study on Zykadia to treat patients with ALK+ NSCLC.
- Reuters•2 days ago
Novartis's Zykadia drug performed well against a rare form of lung cancer, the Swiss company said on Friday, citing a study it hopes will help it win expanded regulatory approval for the use of the drug. Novartis released results of a phase III clinical trial of Zykadia, or ceritinib, on previously untreated patients with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer. Patients treated with Zykadia showed a significant improvement in their chances of surviving without the cancer spreading compared with standard chemotherapy, the firm said.
- Insider Monkey•3 days ago
Results for a potentially game-changing proof of concept study were just published concerning malaria by Novartis AG (NYSE:NVS) in the New England Journal of Medicine. The results show that KAF156, a new antimalarial compound, has demonstrated activity in opposition to both falciparum and vivax malaria and artemisinin-resistant parasites. Malaria, A Life Threatening Disease Malaria is a mosquito-borne life-threatening […]
NOVARTIS AG CEDEAR EACH REP 0.5 (NVS.BA)
Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
|Day's Range||585.00 - 585.00|
|52wk Range||585.00 - 605.50|
|1y Target Est||N/A|
|P/E Ratio (ttm)||N/A|
|Avg Vol (3m)||32|
|Dividend & Yield||N/A (N/A)|